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Abstract
Background: Mucopolysaccharidosis type II (MPSII) patients frequently suffer from dyspnoea caused by restrictive
airway disease due to skeletal abnormalities as well as glycosaminoglycans (GAG) accumulation at different levels of
the airway, including the trachea. In this study we describe the extent of the tracheal and bronchial narrowing, the
changes in airway diameter during respiration and the effects of these obstructions on respiratory function in adult
MPSII patients.
Methods: Five adult MPSII patients (mean age 40 years) were included. Pulmonary function tests and in- and expiratory
chest CT scans were obtained. Cross-sectional areas of trachea and main bronchi were measured at end-inspiration and
-expiration and percentage collapse was calculated.
Results: There was diffuse narrowing of the entire intra-thoracic trachea and main bronchi and severe expiratory collapse
of the trachea in all patients. At 1 cm above the aortic arch the median % collapse of the trachea was 68 (range 60 to
77 %), at the level of the aortic arch 64 (range 21–93 %), for the main bronchi this was 58 (range 26–66 %) on the left and
44 (range 9–76 %) on the right side. The pulmonary function tests showed that this airway collapse results in obstructive
airway disease in all patients, which was severe (forced expiratory volume <50 % of predicted) in four out of five patients.
Conclusion: In adult MPS II patients, central airways diameters are strikingly reduced and upon expiration there is
extensive collapse of the trachea and main bronchi. This central airways obstruction explains the severe respiratory
symptoms in MPSII patients.
Keywords: Adults, Airway obstruction, Mucopolysaccharidoses, Mucopolysaccharidosis type II, Respiratory function tests,
Respiratory system abnormalities/complications, Tomography, X-Ray computed, Trachea abnormalities
Background
Mucopolysaccharidosis type II (MPSII or Hunter syn-
drome; OMIM +309900) is a rare, X-linked disease
characterized by lysosomal accumulation of the gly-
cosaminoglycans (GAGs) heparan and dermatan
sulfate due to deficiency of the enzyme iduronate-2-
sulfatase. The intralysosomal accumulation of GAGs
causes cellular dysfunction resulting in progressive
damage to various organs and tissues. In approxi-
mately 75 % of patients, progressive neurological and
cognitive decline is the most disabling manifestation
of the disease and these severely affected patients die
in first or second decade of life. The remaining pa-
tients, further referred to as non-neuronopathic pa-
tients, have normal cognitive function [1, 2]. Other
prominent signs and symptoms of MPSII are typical
facial features, Ear-Nose-Throat (ENT) infections and
hearing defects, cardiac valve pathology, respiratory
disease, skeletal changes, reduced joint mobility and
hernias. Extent of organ involvement and disease pro-
gression are highly variable between patients [3].
Dyspnea is a frequent symptom in MPSII patients of
multifactorial etiology. First, GAGs accumulate in mucosa
and soft tissues of the throat leading to enlargement of the
larynx, tonsils, adenoids and tongue resulting in reduced
upper airway mobility and obstruction. Second, the altered
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thorax shape and limited mobility of the ribs and intercos-
tal soft tissue often causes restrictive airway disease [4].
Third, tracheobronchomalacia causes airway obstruction.
Tracheobronchial narrowing has been previously de-
scribed in children and adults with MPSII [5–9].
To date changes in airway diameter during respiration
in MPSII patients has not been systematically studied.
After observing a high prevalence of severe respiratory
symptoms in adult MPSII patients, we decided to investi-
gate the tracheobronchial collapsibility of these patients
by performing pulmonary function tests (PFTs) and in-
and expiratory chest CT scans.
Methods
In this study, all adult MPSII patients attending the adult
metabolic outpatient clinic at the Erasmus MC, Rotterdam,
the Netherlands were included. All patients signed in-
formed consent for a long-term follow-up study, of which
pulmonary evaluation is a part. This study was approved by
the Medical Ethical Committee of the Erasmus University
Medical Center. Written informed consent was obtained
from all participants.
Pulmonary function tests
PFTs were obtained in all patients as part of routine
follow-up. Spirometry was performed in accordance with
American Thoracic Society standards [10]. Values of
percent-predicted for spirometry were calculated using
reference values based on age, height, sex and race [11].
The basic parameters used to properly interpret lung
function were the vital capacity (VC), forced expiratory
volume in 1s (FEV1), FEV1/VC ratio and total lung cap-
acity (TLC) [11]. The carbon monoxide diffusing capacity
(DLCO) and adjusted DLCO for the measured lung vol-
ume (DLCO/VA) assisted to diagnose the underlying dis-
ease, when interpreted in conjunction with the lung
volumes assessment. Airway obstruction was defined by
reduction of the FEV1/VC ratio (also known as Tiffeneau-
index) below 70 %. A Tiffenau-index below 70 % depicts a
disproportionate reduction of maximal airflow from the
lung in relation to the maximal expiratory volume (VC),
implying airway narrowing during exhalation. The severity
of lung function impairment was based on the forced ex-
piratory volume in 1s as a percentage of the normal pre-
dicted value, corrected for sex, age, height and race
(FEV1%pred). A restrictive ventilatory defect is character-
ized by a reduction in total lung capacity (TLC) below
80 % of the predicted value. TLC was measured by He-
lium [He] dilution (TLC-He) in all patients and addition-
ally by whole-body plethysmography (TLC-Pleth) in a
single patient. In body plethysmography, breathing ma-
noeuvres are performed in an airtight box of known vol-
ume with fixed barometric pressure. The two techniques
for measuring TLC yield similar results for those with
normal lung mechanical function but can yield differential
results in patients with airflow obstruction. Whole-body
plethysmography is more accurate because of the detec-
tion of poorly or non-ventilated lung areas, also known as
trapped air. A higher TLC measured by bodyplethysmo-
graphy compared to that measured by Helium dilution is
therefore indicative of air trapping [12].
Airway imaging and imaging analysis
We performed in- and expiratory chest CT scans in all pa-
tients. Chest CT was done on different multi-detectors
CT scanners, with detectors ranging from 64 (SOMATON
Definition AS+, SIEMENS Healthcare, Forchheim,
Germany) to 192 (SOMATOM Force, SIEMENS Health-
care, Forchheim, Germany) detectors. CT protocol in-
cluded an end-inspiratory and -expiratory scan starting
from 2 cm above the lung apices to the bases. Instructions
for voluntary breath holds were given before scanning by
the CT technician. Scanning parameters were: collimation
0.625 mm, 50 % overlap, slice thickness 1 mm, pitch 1,
110 kV tube voltage and tube current adapted to recom-
mended volumetric computer tomography dose index
(CTDIvol), which is 1.6 mGy per adult subject. For expira-
tory CTs, image quality was considered sufficient using a
tube current fixed at 25 mA with an effective tube
current-time product of 10 mAs; producing a lower radi-
ation dose than the inspiratory protocol. No contrast
agent was administered. Images were reconstructed with a
2 mm slice thickness as multiplanar reformats (MPR) in
the coronal and sagittal planes. Sharp reconstruction ker-
nel filter without under- or overshoot at edges were used
for central airway measurements.
Images were transferred to the Myrian dicom viewer
(Intrasense, Montpellier, France). Cross-sectional area
(CSA) was measured using a manual tracing tool perpen-
dicular to the tracheal midline. To obtain images perpen-
dicular to the midline, double-oblique reformats were
obtained by the axial MPR with sharp kernel (i.e. B50f,
I70f, B75f) [13] (Ciet et al. 2015). Measurements of CSA
were obtained at five levels throughout the central air-
ways: 1 cm above the aortic arch, at the level of the aortic
arch, 2 cm above the carina, 1 cm below carina in the
main left and right bronchi (Fig. 1a). CSA measurements
were performed with constant lung window (WL -600;
WW 1200) both in the end-inspiratory and at end-
expiratory images by a single radiologist with extensive
experience in thoracic radiology. The percentage airway
collapse was calculated according the formula:
Δ % ¼ CSAins−CSAexp
CSAins
 100:
Where Δ % is the percentage collapse, and CSAins
and CSAexp are the CSA in the end-inspiratory and
expiratory images respectively.
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Results
Patient characteristics
Five adult MPSII patients were enrolled in the study
(mean age 40 years, age range 29–50). All patients were
male and had normal cognitive function. Four out of five
patients were diagnosed during childhood (age range 3
to 9 years), one patient was diagnosed at adult age (age
45 years). In the latter patient the disease was the least
severe and only at age 45 the cluster of ENT problems,
recurrent pulmonary infections, cardiac valve pathology
and skeletal problems were recognized as being caused
by MPS II. In all five patients, enzyme replacement ther-
apy (ERT) was started and all but one received ERT at
the time of the pulmonary evaluation. Duration of ERT
at time of evaluation ranged from 3 months to 7 years.
The single untreated patient discontinued ERT 4 years
prior to the evaluation because of recurrent anaphylactic
reactions during enzyme infusion. At the time, he had
been treated for 2 years. Patient characteristics are sum-
marized in Table 1. Three patients received nightly ven-
tilatory support, in one this was bilevel positive airway
pressure (BiPAP) and in the other two continuous posi-
tive airway pressure (CPAP) (Table 2).
Pulmonary function
Table 2 shows the results of the PFT measurements, per-
formed at a time point closest to the airway imaging
date (median time gap 14 days). In patients 1, 2, 4 and 5
the lung function analysis showed airway obstruction
(FEV1/VC <0.7). In three patients this was accompanied
by restriction as the total lung capacity (TLC) measured
was below 80 % of predicted. Thus, mixed obstructive
and restrictive airway disease was present in these
patients. Patient 1 showed only obstructive airway
Fig. 1 In- and expiratory chest CT scan. a Central airways measurements were performed at five locations: (a) 1 cm above aortic arch, (b) aortic arch,
(c) 2 cm above carina bifurcation, (d) right main bronchus, (e) left main bronchus. b Tracheal cross section at “b” (1 cm above the aortic arch) in patient 2.
Note abnormal “bell-shaped” trachea in the end-inspiration image. c At end expiration there is almost complete collapse of the trachea (same patient).
d Bronchial cross section at “e”(left main bronchus) at end inspiration (patient 2) and e at end expiration (same patient). f Presence of trapped air at
expiration (patient 1)
Table 1 Patient characteristics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Mutation c.806A > T c.1024 C > T c.182 C > A c.1265G > A c.1122C > T
Age (years) 49 45 43 31 29
Age at diagnosis 7 45 7 9 3
Height (m) 1.71 1.76 1.61 1.52 1.44
Weight (kg) 91 111 60 51 44
Age start ERT therapy 47 45 37 25 25
Currently on ERT therapy Yes Yes No Yes Yes
Duration of ERT therapy (years) 2 0.25 2 7 4
N/A not applicable, ERT enzyme replacement therapy
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disease. Patient 3 appeared to have only restrictive air-
way disease but the marked difference between TLC
measured by body plethysmography (60 %) and TLC-He
(49 %) was suggestive of trapped air, which is usually
seen in the context of airway obstruction. The concave
shape of the expiratory part of the flow volume loop was
indeed indicative of airflow obstruction (Additional file
1: Figure S1). Thus, patient three also had obstructive
airway disease.
In patient 4 the airway impairment was very severe
(FEV1%pred <35). In patients 1, 3 and 5 the airway im-
pairment was severe (FEV1%pred <50). Patient 2 had
moderate airway impairment (FEV1%pred 61). This was
the patient diagnosed at adulthood, with an overall mild
MPSII phenotype.
Diffusing capacity was normal in all patients. The low
DLCO but normal DLCO/VA excludes parenchymal dis-
ease and indicates extraparenchymal abnormalities. In
MPSII these extraparenchymal abnormalities are the
anomalous thorax shape and mechanics caused by thor-
acic spine and rib deformities [4].
Airway imaging
All patients successfully completed the CT protocol. In
the inspiratory imaging, all patients had diffusely nar-
rowed and thickened trachea and main bronchi. The tra-
chea showed an abnormal triangular shape with
flattening of the cartilaginous portion and enlargement
of the pars membranacea (Fig. 1b). As a result, the CSA
was already significantly reduced in the end-inspiratory
images.
Severe expiratory collapse of the trachea was seen in
all patients. Table 3 described the central airways
measurements at five different locations at end-
inspiration and -expiration and the percentage collapse
for each patient. Median percentage collapse at different
levels of the airway were: 68 % at 1 cm above the aortic
arch), 64 % at the level of the aortic arch, 58 % 2 cm
above the carina. Main bronchi collapse measured at
1 cm below carina was 58 % for the left main bronchus
and 44 % for the right main bronchus (Fig. 1b-e). Be-
cause of the already diffusely narrowed central airway
lumen in inspiration, the remaining airway lumen at end
expiration is much smaller than if the collapse would
have occurred in a normally shaped trachea. In the most
severely affected patient, there was an almost complete
closure of the trachea during expiration. The expiratory
chest scan also showed the presence of trapped air in all
but one patient (Fig. 1f ).
Discussion
This study shows extensive collapse of the trachea and
main bronchi, resulting life threatening airway obstruc-
tion in adult MPSII patients. Airway collapse was
present in all patients included in this study. Adult
MPSII patients have severely reduced central airway
calibre caused by diffuse tracheobronchomalacia. Previ-
ous studies in younger MPSII patients [14, 15] (Wooten
et al. 2013 median age 9 years n = 30, Lin et al. 2014
mean age 18 years n = 12) reported PFT outcomes. In
these younger patients, mainly restrictive airway disease
was observed. In the study of Lin et al. [15], the oldest
MPSII patients (age 24 and 33 years) also showed mixed
restrictive and obstructive airway disease. In that study,
there was a clear negative correlation between age and
FEV1, indicative of worsening of pulmonary function
Table 2 Pulmonary function tests
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
VC max (L) 4.01 3.79 1.83 1.5 2.01
VC max (%) 91 78 46 40 61
FEV1 (L) 1.32 2.33 1.36 0.55 1.18
FEV1 (%) 38 62 43 18 41
Tiffeneau (FEV1/VC) (%) 33 61 74 37 59
TLC-He (L) 5.52 5.38 2.84 3.6 2.94
TLC-He (%) 84 77 49 71 66
TLC-Pleth 3.50
TLC-Pleth (%) 60
DLCO (%) 73 94 46 44 43
DLCO/VA(%) 108 140 132 109 129
Age at time of start ventilatory support 50 N/A 40 31 N/A
Type of ventilatory support CPAP N/A BiPAP CPAP N/A
VC vital capacity (in litre and as % of predicted), FEV1 forced expiratory volume in 1 s (in litre and as % of predicted), TLC-He total lung capacity measured by
helium dilution (in litre and as % of predicted), TLC-Pleth total lung capacity measured by bodyplethysmography (in liter and as % of predicted), DLCO carbon
monoxide diffusing capacity (% of predicted), DLCO/VA carbon monoxide diffusing capacity adjusted for lung volume (% of predicted). CPAP continuous positive
airway pressure, BiPAP bilevel positive airway pressure
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with increasing age. Our study shows that in non-
neuronopathic MPSII patients aged 30 years or older,
pulmonary function is more severely compromised than
in younger patients and that this is mainly due to pro-
gression of the obstructive component of the airway dis-
ease. The cause of this progression is thought to be due
to the increasing tracheal and bronchial obstruction and
collapse.
The observed severe expiratory collapse of the trachea
and main bronchi can explain the high rate of deaths
caused by airway impairment in adult MPSII patients
[2]. In one of our patients (patient 3), there was almost
complete closure of the trachea upon expiration
(Table 3). The clinically most severely affected patients
(patient 3 and 4) were the patients with by far the smal-
lest expiratory diameter of the trachea at the level of the
aortic arch and 2 cm above the carina (Table 3).
In patient 3, nightly bilevel positive airway pressure
(BiPAP) was started when respiratory insufficiency was de-
tected (mean transcutaneous CO2 8.5 KPa) resulting in
improvement of symptoms and normalisation of the
pCO2 levels. In patient 4 there were progressive respira-
tory symptoms despite early antibiotic treatment in case
of suspected pulmonary infection, oral steroid therapy to
reduce airway inflammation and inhaled bronchodilator
therapy. Because of progressive airway obstruction due to
severe tracheobronchial collapse together with increased
sputum production due to reduced mucocilliary clearance,
nightly CPAP therapy was started with a significant reduc-
tion in work of breathing and improvement in respiratory
symptoms. In this patient, placement of a tracheostomy or
tracheal stent was discussed, but not pursued because of
the severity and extensiveness of the airway obstruction,
involving the entire trachea and main bronchi.
There is an additional value of airway imaging com-
pared to PFTs alone in the assessment of respiratory
symptoms in MPSII patients. For example, in patient 3
standard lung function tests could not explain his severe
respiratory symptoms. Additional body plethysmography
suggested obstructive airway disease and trapped air that
was confirmed by CT scanning. Thus, the combination
of these tests was necessary to correctly identify the ori-
gin of the severe respiratory symptoms.
In addition to management of the respiratory symp-
toms, knowledge of airway form and function in
MPSII patients is important for planning surgical pro-
cedures. Pre-anesthesia airway evaluation should in-
clude fibroscopic inspection of the upper airway and
PFTs. Based on this study we also recommend to per-
form (dynamic) airway imaging by chest CT scan to
assess airway morphology. In this manner a compre-
hensive multidisciplinary approach to peri-operative
airway management can be achieved. Possible con-
cerns related to radiation exposure deriving by the
use of CT is likely overcome by the severity of the
central airway obstruction. Moreover, thanks to mag-
netic resonance imaging (MRI), this limitation might
be resolved, as shown in a recent study in pediatric
patients with tracheobronchomalacia [16].
Respiratory pathology in MPS is thought to arise
from the accumulation of GAGs at different levels of
the airway. Histopathological studies in MPS II have
shown GAG accumulation in adenoidal and supraglot-
tic tissues [17], but accumulation in tracheal tissues
has, to our knowledge, only been shown in MPS I
and mucolipidosis patients [18]. Collapsibility of the
trachea has not been studied in other forms of MPS
then MPS II. Gross histopathological examination of
tracheas of MPSII patients showed flattening of the
tracheal cartilage with loss of the anterioposterior
diameter [5]. Whereas in most sites involved in
MPSII GAG accumulation results in stiffness and re-
duced mobility (e.g. cardiac valves, joints, larynx,
skin) in the trachea the result is softening and weak-
ness of the supporting cartilage, resulting in airway
collapse. A factor that might be responsible for this
loss of structural integrity of the cartilage could be
inflammation. In a rodent model for MPS VI, in
which full collapse of the trachea usually occurs by
9 months of age, two forms of anti-inflammatory
treatment resulted in an increased tracheal lumen and
a thicker tracheal wall compared to untreated rats
[19, 20]. As such, anti-inflammatory therapy may be
of value in the treatment of the severe tracheabronch-
omalacia, since ERT does not seem to prevent the oc-
currence of this life-threatening disease manifestation.
Table 3 In- and expiratory cross sectional areas at different levels of the central airway
Location Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
1 cm above aortic arch 0.83→ 0.32 (61 %) 2.21→ 0.63 (71 %) 1.66→ 0.67 (60 %) 0.81→ 0.26 (68 %) 0.84→ 0.19 (77 %)
Aortic arch 1.02→ 0.39 (62 %) 2.08→ 0.75 (64 %) 1.58→ 0.11 (93 %) 0.35→ 0.12 (66 %) 0.87→ 0.69 (21 %)
2 cm above carina 1.04→ 0.53 (49 %) 2.07→ 0.98 (53 %) 1.59→ 0.27 (83 %) 0.3→ 0.3 (0 %) 0.80→ 0.53 (34 %)
1 cm below carina left main bronchus 0.54→ 0.4 (26 %) 1.16→ 0.4 (66 %) 1.04→ 0.41 (61 %) 0.31→ 0.13 (58 %) 0.53→ 0.34 (36 %)
1 cm below carina right main bronchus 0.52→ 0.29 (44 %) 1.33→ 0.65 (51 %) 1.55→ 0.37 (76 %) 0.54→ 0.49 (9 %) 0.64→ 0.56 (13 %)
Before arrow: cross sectional area in cm at end inspiration, after the arrow: cross sectional area at end expiration in cm, in brackets percentage airway lumen collapse
between end-inspiratory and end-expiratory imaging
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Conclusions
In adult MPSII patients, severe tracheal and bronchial
collapse result in obstructive airway disease leading to
trapped air. In combination with the restrictive lung dis-
ease present in these patients, this can lead to respira-
tory insufficiency and complete respiratory arrest,
especially during airway infections. Because of the very
specific nature of the airway pathology tailored therapy,
such as modified non-invasive ventilation, is required.
Additional file
Additional file 1: Figure S1. Flow-volume curve patient 3. In this
patient, the FEV1/VC was above 70 %, which does not indicate obstructive
airway disease. However, the concave shape of the expiratory part of the
flow-volume loop is compatible with airway obstruction which fits with the
imaging results. The discrepancy between the FEV1/VC value and the other
findings is explained by the presence of trapped air. (PPTX 53 kb)
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